Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CUCA
- Development stage
- Unknown
- Lead developer
- Berko İlaç
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
CUCA is an over-the-counter liquid food supplement developed and marketed by Berko İlaç. It contains 20% liquid fig (*Ficus carica*) fruit extract, providing 1000 mg of fig extract per 5 mL dose. CUCA is designed to support gastrointestinal health, promote intestinal peristalsis, and alleviate constipation. The natural dietary fibers, pectins, and active components within the fig extract help increase fecal bulk, soften stool consistency, and improve overall bowel regularity.
- Brand names
- CUCACUCA 20%
- Other names
- CUCA 20% SyrupCUCA SyrupFicus carica fruit extractfig extractliquid fig extract
Beyond the preview
Go deeper on CUCA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CUCA.